Patients with Long COVID continue to experience significant symptoms at 12 months and factors associated with improvement: A prospective cohort study in France (PERSICOR).

Publication date: Mar 01, 2024

This study examines long COVID symptoms course over 12 months, their impact on daily life, and associated factors for symptom relief. A prospective cohort study included 231 participants with long COVID at 12-month follow-up. Data on characteristics, symptom course, and remission were collected using a questionnaire and a remission scale. Poisson regression models were used to estimate the prevalence rate ratio (PRR) and 95% confidence intervals (CIs) for factors associated with symptom improvement. Of the 231 participants, 63. 2% developed SARS-CoV-2 antibodies before COVID-19 vaccination. At 12 months, only 8. 7% (95% CI: 5. 4-13. 1%) reported complete remission, while 28. 6% noted significant improvement. Most symptoms remained prevalent: asthenia (83. 1%), neurocognitive/neurological (93. 9%), cardiothoracic (77. 9%), Musculoskeletal (78. 8%). During long COVID, 62. 2% stopped working, and only 32. 5% resumed full-time professional activities. Presence of SARS-CoV-2 antibodies before vaccination increased the probability of improvement (aPRR: 1. 60, P = 0. 028), while ageusia at initial long COVID phase decreased the probability (aPRR: 0. 38, P = 0. 007). Long-COVID symptoms persisted in the majority of participants after 12 months, with significant impacts on daily life and work. SARS-CoV-2 antibodies were associated with better prognosis, while persistent ageusia indicated a lower probability of improvement. These findings highlight the need for ongoing support and care for individuals with long COVID.

Concepts Keywords
Cardiothoracic Antibodies cognitive impairment
Increased Follow-up
Month Long COVID
Professional SARS-CoV-2
Vaccination Social consequences

Semantics

Type Source Name
disease MESH Long COVID
disease IDO symptom
disease MESH COVID-19
disease VO vaccination
disease VO time
drug DRUGBANK Tropicamide
disease MESH cognitive impairment
disease MESH sequelae

Original Article

(Visited 1 times, 1 visits today)